The Prognostic Value of Olfactory Dysfunction in Patients with COVID-19: The COVIDORA Study.

The Prognostic Value of Olfactory Dysfunction in Patients with COVID-19: The COVIDORA Study.

Publication date: Feb 22, 2024

Among all studies describing COVID-19 clinical features during the first wave of the pandemic, only a few retrospective studies have assessed the correlation between olfac-tory dysfunction (OD) and the evolution of disease severity. The main aim was to assess whether OD is a predictive factor of COVID-19 severity based on the patient’s medical management (outpa-tient care, standard hospital admission, and ICU admission). A national, prospective, mul-ticenter cohort study was conducted in 20 public hospitals and a public center for COVID-19 screen-ing. During the first wave of the pandemic, from 6 April to 11 May 2020, all patients tested positive for COVID-19 confirmed by RT-PCR underwent two follow-up ENT consultations within 10 days of symptom onset. The main outcome measures were the evolution of medical management (out-patient care, standard hospital admission, and ICU admission) at diagnosis and along the clinical course of COVID-19 disease. Among 481 patients included, the prevalence of OD was 60. 7%, and it affected mostly female patients (74. 3%) under 65 years old (92. 5%), with fewer comor-bidities than patients with normal olfactory function. Here, 99. 3% (290/292) of patients with OD presented with non-severe COVID-19 disease. Patients reporting OD were significantly less hospi-talized than the ones managed as outpatients, in either a standard medical unit or an ICU. Conclu-sions: As regards the clinical course of COVID-19 disease, OD could predict a decreased risk of hospitalization during the first wave of the pandemic.

Open Access PDF

Concepts Keywords
Basel anosmia
Cohort COVID-19
Hospitalization diabetes
Tory hypertension
olfactory dysfunction
parosmia
phantosmia
renal insufficiency
risk factors
taste dysfunction
tobacco

Semantics

Type Source Name
disease MESH COVID-19
disease IDO symptom
disease MESH clinical course
drug DRUGBANK Etodolac
drug DRUGBANK Diethylstilbestrol
drug DRUGBANK Coenzyme M
disease MESH Genetic Diseases
drug DRUGBANK L-Aspartic Acid
drug DRUGBANK L-Citrulline
disease MESH phantosmia
disease MESH taste dysfunction
disease MESH hypertension
disease MESH renal insufficiency
disease MESH infection
disease VO time
drug DRUGBANK Pentaerythritol tetranitrate
disease VO population
disease VO nose
disease IDO assay
disease IDO history
disease MESH nasal polyps
disease IDO process
drug DRUGBANK Corticorelin
disease MESH allergy
disease MESH chronic disease
disease IDO immunosuppression
disease MESH paresthesia
drug DRUGBANK Budesonide
drug DRUGBANK Vitamin A
drug DRUGBANK Esomeprazole
disease MESH obesity

Original Article

(Visited 1 times, 1 visits today)